Acquired resistance to targeted therapy remains a major limitation to clinical benefit in
oncology. Understanding mechanisms of resistance can potentially lead to novel strategies …

In the past few years, the mechanisms leading to an acquired resistance to anti-EGFR
monoclonal antibodies became an important topic in metastatic colorectal cancer research …

Abstract Purpose: Even if RAS-BRAF wild-type and HER2/MET–negative metastatic
colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired …

The field of targeted therapy provides exciting opportunities for improving oncological
outcomes. Over the last decade it has evolved exponentially and the list of approved drugs …

© AME Publishing Company. All rights reserved. Transl Gastrointest Cancer 2013; 2 (1): 44-
46 www. amepc. org/tgc acquired resistance have been developed through prolonged …

Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR)
monoclonal antibodies used as therapies for metastatic colorectal cancer patients. Intrinsic …

The anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies cetuximab
and panitumumab have been demonstrated to be new therapeutic options for metastatic …

The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic
colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and …

Metastatic colorectal cancer (mCRC) continues to be counted as a major health problem.
The introduction of newer cytotoxics, irinotecan and oxaliplatin, has achieved a significant …

Background Treatment with anti-EGFR antibody has been shown to prolong survival in
patients with RAS wild-type metastatic colorectal cancer (mCRC). However, even patients …